Skip to main content
. 2011 Mar 28;11:112. doi: 10.1186/1471-2407-11-112

Figure 7.

Figure 7

Inhibition of caspase activation did not affect loss of STAT3 following FLLL32 treatment. A) Canine (OSA8) and human (SJSA) OSA cell lines were pretreated with the pan-caspase inhibitor 80 μM Z-VAD-FMK or DMSO for 2 or 24 hours then treated with DMSO or 10 μM FLLL32 for 18 hours. Protein lysates were generated and separated by SDS-PAGE and western blotting for STAT3, PARP, and β-actin was performed. Experiments were repeated two times. B) Canine (OSA8) or human (SJSA) OSA cell lines were pretreated with the pan-caspase inhibitor 80 μM Z-VAD-FMK, DMSO, or media for 2 or 24 hours then treated with media, DMSO, or 10 μM FLLL32 for 18 hours. Caspase-3/7 activity was measured using the SensoLyte® Homogeneous AMC Caspase-3/7 Assay kit. Experiments were performed in triplicate and repeated two times.